{"id":14966,"date":"2012-06-12T10:30:00","date_gmt":"2012-06-12T08:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/glaxosmithkline-rileva-il-toctino\/"},"modified":"2012-06-12T10:30:00","modified_gmt":"2012-06-12T08:30:00","slug":"glaxosmithkline-rileva-il-toctino","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/glaxosmithkline-rileva-il-toctino\/","title":{"rendered":"GlaxoSmithKline detects Toctino"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"text-align: right; line-height: 13.5pt; margin: 0cm 0cm 0pt\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #222222; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT; mso-no-proof: yes\"><shapetype id=\"_x005F_x0000_t75\" o_spt=\"75\" o_preferrelative=\"t\" filled=\"f\" stroked=\"f\" path=\"m@4@5l@4@11@9@11@9@5xe\" coordsize=\"21600,21600\"><stroke joinstyle=\"miter\"><\/stroke><formulas><f eqn=\"if lineDrawn pixelLineWidth 0\"><\/f><f eqn=\"sum @0 1 0\"><\/f><f eqn=\"sum 0 0 @1\"><\/f><f eqn=\"prod @2 1 2\"><\/f><f eqn=\"prod @3 21600 pixelWidth\"><\/f><f eqn=\"prod @3 21600 pixelHeight\"><\/f><f eqn=\"sum @0 0 1\"><\/f><f eqn=\"prod @6 1 2\"><\/f><f eqn=\"prod @7 21600 pixelWidth\"><\/f><f eqn=\"sum @8 21600 0\"><\/f><f eqn=\"prod @7 21600 pixelHeight\"><\/f><f eqn=\"sum @10 21600 0\"><\/f><\/formulas><path o_extrusionok=\"f\" gradientshapeok=\"t\" o_connecttype=\"rect\"><\/path><lock v_ext=\"edit\" aspectratio=\"t\"><\/lock><\/shapetype><\/span><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #222222; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT; mso-no-proof: yes\"><shape id=\"Immagine_x005F_x0020_1\" o_spid=\"_x005F_x0000_i1025\" alt=\"Descrizione: http:\/\/www.cdt.ch\/images\/dot.png\" type=\"#_x005F_x0000_t75\" style=\"width: 6.5pt; height: 6.5pt; visibility: visible; mso-wrap-style: square\"><imagedata src=\"file:\/\/\/C:UsersAngeloAppDataLocalTempmsohtmlclip1\u00001clip_image001.png\" o_title=\"dot\"><\/imagedata><\/shape><img loading=\"lazy\" decoding=\"async\" id=\"il_fi\" alt=\"\" width=\"221\" height=\"55\" style=\"padding-bottom: 8px; padding-right: 8px; padding-top: 8px\" src=\"http:\/\/www.toctino.co.uk\/images\/toctino\/toctino_logo.jpg\" \/><\/span><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #222222; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><\/p>\n<p><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: 13.5pt; margin: 0cm 0cm 15pt\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #222222; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><font size=\"3\">BASILEA &#8211; Accordo globale sul Toctino, un preparato contro l&#8217;eczema alle mani: attraverso la societ&agrave; Stiefel, il gruppo britannico GlaxoSmithKline ha rilevato dalla societ&agrave; farmaceutica renana Basilea i diritti esclusivi mondiali di sviluppo, produzione, commercializzazione e distribuzione del farmaco.<\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: 13.5pt; margin: 0cm 0cm 15pt\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: #222222; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT\"><font size=\"3\">L&#8217;industria farmaceutica Basilea ottiene in cambio un versamento iniziale di 146 milioni di sterline (216 milioni di franchi) e il diritto ad altri pagamenti fino a 50 milioni di sterline. User&agrave; questo denaro da una parte per ritentare di ottenere l&#8217;omologazione dell&#8217;antibiotico Ceftobiprol nella Ue e dall&#8217;altra per sviluppare prodotti come un farmaco contro le micosi, l&#8217;Isavuconazol.<\/p>\n<p><\/font><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 10pt\"><i style=\"mso-bidi-font-style: normal\"><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt; mso-fareast-font-family: 'Times New Roman'; mso-fareast-language: IT; mso-bidi-font-weight: bold\">12.06.2012 &#8211; 08:01 Corriere del Ticino<\/p>\n<p><\/span><\/i><\/p>\n<p style=\"text-align: left\">&nbsp;<img loading=\"lazy\" decoding=\"async\" id=\"il_fi\" alt=\"\" width=\"158\" height=\"70\" style=\"padding-bottom: 8px; padding-right: 8px; padding-top: 8px\" src=\"http:\/\/www.medicines.org.uk\/services\/internalservices\/companylogo\/img\/org3336pro1.gif\" \/><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; line-height: normal; margin: 0cm 0cm 0pt; background: white\"><a name=\"top\"><\/a><span","protected":false},"excerpt":{"rendered":"<p>BASILEA &#8211; Accordo globale sul Toctino, un preparato contro l&#8217;eczema alle mani: attraverso la societ&agrave; Stiefel, il gruppo britannico GlaxoSmithKline ha rilevato dalla societ&agrave; farmaceutica renana Basilea i diritti esclusivi mondiali di sviluppo, produzione, commercializzazione e distribuzione del farmaco. L&#8217;industria farmaceutica Basilea ottiene in cambio un versamento iniziale di 146 milioni di sterline (216 milioni &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14966","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14966"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14966\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}